-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbott Announces New Clinical Data From Two Late-Breaking Presentations At AF Symposium In Boston, Showing Strong Safety And Efficacy Of Minimally Invasive Therapies To Treat People With AFib

Benzinga·02/06/2026 13:03:45
Listen to the news
  • Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System's industry-leading success rate for treating AFib1
  • New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to significantly reduce AFib episodes for complex cases2

ABBOTT PARK, Ill., Feb. 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation (AFib). The results include 12-month findings that reinforce the long-term safety and performance of Abbott's Volt™ Pulsed Field Ablation (PFA) System, which were simultaneously published in JACC: Clinical Electrophysiology. Positive results were also presented on Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, a dual-energy, focal ablation catheter engineered to allow physicians to tailor how they deliver AFib therapy.